Abstract
David Dowdy and colleagues discuss the complexities of costing new TB diagnostic tests, including GeneXpert, and argue that flexible analytic tools are needed for decision-makers to adapt large-sample cost-effectiveness data to local conditions.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cost-Benefit Analysis
-
False Positive Reactions
-
Humans
-
Molecular Diagnostic Techniques / economics*
-
Mycobacterium tuberculosis / classification
-
Mycobacterium tuberculosis / genetics
-
Mycobacterium tuberculosis / isolation & purification*
-
Polymerase Chain Reaction / economics*
-
Sensitivity and Specificity
-
Tuberculosis, Pulmonary / diagnosis*
-
Tuberculosis, Pulmonary / microbiology